WO2007010032A3 - Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif - Google Patents

Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif Download PDF

Info

Publication number
WO2007010032A3
WO2007010032A3 PCT/EP2006/064502 EP2006064502W WO2007010032A3 WO 2007010032 A3 WO2007010032 A3 WO 2007010032A3 EP 2006064502 W EP2006064502 W EP 2006064502W WO 2007010032 A3 WO2007010032 A3 WO 2007010032A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
desoxylactitol
alkylamino
active ingredient
association complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/064502
Other languages
English (en)
Other versions
WO2007010032A2 (fr
Inventor
Sabrina Consola
Muriel Blanzat
Isabelle Rico-Lattes
Emile Perez
Pascal Bordat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Dermo Cosmetique SA
Universite de Toulouse
Original Assignee
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Dermo Cosmetique SA
Universite Toulouse III Paul Sabatier
Universite de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Pierre Fabre Dermo Cosmetique SA, Universite Toulouse III Paul Sabatier, Universite de Toulouse filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002616091A priority Critical patent/CA2616091A1/fr
Priority to BRPI0613671-0A priority patent/BRPI0613671A2/pt
Priority to JP2008521980A priority patent/JP2009502764A/ja
Priority to EP06777885A priority patent/EP1917036A2/fr
Priority to US11/989,210 priority patent/US20090137656A1/en
Publication of WO2007010032A2 publication Critical patent/WO2007010032A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007010032A3 publication Critical patent/WO2007010032A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Complexe d'association intermoléculaire de formule (I) d'un transporteur amphiphile et d'un principe actif Z-Y: dans lequel S, X, n, R1, R2, R3, Y, Z sont tels que définis dans la description. De préférence, le transporteur amphiphile est un N-alkylarnino-1-déoxylactitol. De péférence le principe actif est choisi parmi l'indométhacine, l'ibuprofène, le kétoprofène ou l'acide linoléique.
PCT/EP2006/064502 2005-07-22 2006-07-21 Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif Ceased WO2007010032A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002616091A CA2616091A1 (fr) 2005-07-22 2006-07-21 Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
BRPI0613671-0A BRPI0613671A2 (pt) 2005-07-22 2006-07-21 complexo de associação intermolecular de um transportador e de um princìpio ativo
JP2008521980A JP2009502764A (ja) 2005-07-22 2006-07-21 担体と有効成分の分子間結合錯体
EP06777885A EP1917036A2 (fr) 2005-07-22 2006-07-21 Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
US11/989,210 US20090137656A1 (en) 2005-07-22 2006-07-21 Intermolecular Association Complex of a Carrier and of an Active Principle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507856A FR2888752B1 (fr) 2005-07-22 2005-07-22 Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
FR0507856 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007010032A2 WO2007010032A2 (fr) 2007-01-25
WO2007010032A3 true WO2007010032A3 (fr) 2008-06-19

Family

ID=36218212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064502 Ceased WO2007010032A2 (fr) 2005-07-22 2006-07-21 Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif

Country Status (7)

Country Link
US (1) US20090137656A1 (fr)
EP (1) EP1917036A2 (fr)
JP (1) JP2009502764A (fr)
BR (1) BRPI0613671A2 (fr)
CA (1) CA2616091A1 (fr)
FR (1) FR2888752B1 (fr)
WO (1) WO2007010032A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553099A1 (fr) * 1983-10-11 1985-04-12 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
FR2579895A1 (fr) * 1985-04-05 1986-10-10 Fidia Spa
EP0723972A1 (fr) * 1995-01-30 1996-07-31 Stepan Europe Lactylamines et applications pharmaceutiques
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
EP1449511A1 (fr) * 1999-07-09 2004-08-25 Birgit Neudecker Utilisation d'Idebenone pour la conservation des compositions
WO2006022325A1 (fr) * 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. Dérivé de galactose, vecteur de médicament et préparation thérapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553099A1 (fr) * 1983-10-11 1985-04-12 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
FR2579895A1 (fr) * 1985-04-05 1986-10-10 Fidia Spa
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
EP0723972A1 (fr) * 1995-01-30 1996-07-31 Stepan Europe Lactylamines et applications pharmaceutiques
EP1449511A1 (fr) * 1999-07-09 2004-08-25 Birgit Neudecker Utilisation d'Idebenone pour la conservation des compositions
WO2006022325A1 (fr) * 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. Dérivé de galactose, vecteur de médicament et préparation thérapeutique

Also Published As

Publication number Publication date
FR2888752B1 (fr) 2007-10-05
EP1917036A2 (fr) 2008-05-07
US20090137656A1 (en) 2009-05-28
JP2009502764A (ja) 2009-01-29
BRPI0613671A2 (pt) 2011-01-25
WO2007010032A2 (fr) 2007-01-25
FR2888752A1 (fr) 2007-01-26
CA2616091A1 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2008034736A3 (fr) Dérivés d'oxindole
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2008090066A3 (fr) Stabilisation d'ingrédients actifs sensibles aux ultraviolets
EP2308867A3 (fr) Dérivés 2-OXO-1-Pyrrolidine, leurs procédés de préparation et leurs utilisations
WO2008101682A3 (fr) Nouveaux microbiocides
WO2007048064A3 (fr) Aminopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
TNSN07397A1 (en) Acetylene derivatives
UA104902C2 (uk) Фармацевтичні композиції для запобігання зловживанню лікарськими препаратами
UA94065C2 (en) Dihydropseudoerythromycin derivatives
EP1864665A4 (fr) Agent immunosuppressif et agent anti-tumoral comprenant un compose heterocyclique en tant que principe actif
WO2007139933A3 (fr) Procédés pour la préparation d'acide r-(+)-3-(carbamoyl méthyl)-5-méthylhexanoïque et de sels de celui-ci
TW200728389A (en) Stable polyamides for simultaneous solid phase polymerization of polyesters and polyamides
MX2009005368A (es) Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
WO2009060952A1 (fr) Nouvelle préparation
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
DE502005006070D1 (de) Kosmetische formulierung auf mikroemulsionsbasis enthaltend mandelsäure
NO20092025L (no) Reduksjon av overvekt eller fedme
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées
BRPI0506779A (pt) formulação de sorvete, e, sorvete
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
WO2007010032A3 (fr) Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif
WO2009071691A3 (fr) Dérivés oxindoliques et leur utilisation comme médicament
WO2009075250A1 (fr) Agent phytosanitaire
WO2007007207A8 (fr) Composes de modulation de la profileration cellulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006777885

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/001009

Country of ref document: MX

Ref document number: 2008521980

Country of ref document: JP

Ref document number: 2616091

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11989210

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2006777885

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0613671

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080122